Vol. 5 No. 10 (2025)
Reimbursement Reviews

Polatuzumab Vedotin (Polivy)

decorative image of the issue cover

Published October 28, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Polatuzumab vedotin (Polivy), 30 mg or 140 mg single-use vial, lyophilized powder for solution for IV infusion.
  • Indication: Polivy (polatuzumab vedotin) in combination with R-CHP, indicated for the treatment of adult patients with previously untreated LBCL, including DLBCL NOS, high grade B-cell lymphoma, EBV-positive DLBCL NOS, and T-cell/histiocyte rich LBCL.